Signant Health launches Signant Biotech for emerging biopharma organisations
The research approach will help small- to mid-sized organisations to advance their clinical studies
Read More
Tag: Research & Development
GSK HIV combo meets main goal in Phase III study
The drug could now be administered every eight weeks compared to every four.
Read More
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
